

Sorrento Therapeutics, Inc.  
 Form 4  
 April 17, 2017

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 ABG Management Ltd

(Last) (First) (Middle)

UNIT 3002-3004, 30TH FLOOR,, GLOUCESTER TOWER, THE LANDMARK, CENTRAL

(Street)

HONG KONG, K3 00000

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
 Sorrento Therapeutics, Inc. [SRNE]

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 04/13/2017

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
 \_\_\_ Officer (give title below) \_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

\_\_\_ Form filed by One Reporting Person  
 \_X\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price   |
| Common Stock                    | 04/13/2017                           |  | P                              |   | 1,000,000   | A  | \$ 2  |
|                                 |                                      |  |                                |   | 1,397,853   | I  |   |
|                                 |                                      |  |                                |   | 1,441,441   | I  |   |
|                                 |                                      |  |                                |   | 3,243,242   | I  |   |

Through ABG II-SO Limited (1) (2) (3) (4) (5)

Through Ally Bridge LB Healthcare Master Fund Limited (1) (2) (3) (4) (6)

Through ABG SRNE Limited

Edgar Filing: Sorrento Therapeutics, Inc. - Form 4

|              |            |  |   |           |   |      |           |   |   |
|--------------|------------|--|---|-----------|---|------|-----------|---|---|
|              |            |  |   |           |   |      |           |   | (1) (2) (3) (4) (7)                                   |
| Common Stock | 04/13/2017 |  | P | 1,500,000 | A | \$ 2 | 1,500,000 | I | Through ABG Innovation-SO Limited (1) (2) (3) (4) (8) |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Pr Deri Secu (Inst |                            |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-----------------------|----------------------------|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title                 | Amount or Number of Shares |
| Warrants                                   | \$ 8.5   |                                      |  |                                |   | (9) 05/31/2019   | Common Stock  | 432,432               |                            |
| Warrants                                   | \$ 8.5   |                                      |  |                                |   | (9) 05/31/2019   | Common Stock  | 432,432               |                            |
| Warrants                                   | \$ 8.5   |                                      |  |                                |   | (10) 06/07/2019  | Common Stock  | 540,540               |                            |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |         |       |
|--|---------------|-----------|---------|-------|
|  | Director      | 10% Owner | Officer | Other |
| ABG Management Ltd<br>UNIT 3002-3004, 30TH FLOOR,<br>GLOUCESTER TOWER, THE LANDMARK, CENTRAL<br>HONG KONG, K3 00000                                      |               | X         |         |       |
| ABG SRNE Ltd<br>UNIT 3002-3004, 30TH FLOOR,<br>GLOUCESTER TOWER, THE LANDMARK, CENTRAL<br>HONG KONG, K3 00000  |               | X         |         |       |
| Ally Bridge Group Capital Partners II, L.P.<br>UNIT 3002-3004, 30TH FLOOR,<br>GLOUCESTER TOWER, THE LANDMARK, CENTRAL<br>HONG KONG, K3 00000             |               | X         |         |       |
| ABG II-SO Ltd<br>UNIT 3002-3004, 30TH FLOOR,<br>GLOUCESTER TOWER, THE LANDMARK, CENTRAL<br>HONG KONG, K3 00000   |               | X         |         |       |
| Ally Bridge LB Healthcare Master Fund Ltd<br>UNIT 3002-3004, 30TH FLOOR,<br>GLOUCESTER TOWER, THE LANDMARK, CENTRAL<br>HONG KONG, K3 00000               |               | X         |         |       |
| Ally Bridge LB Management Ltd<br>UNIT 3002-3004, 30TH FLOOR,<br>GLOUCESTER TOWER, THE LANDMARK, CENTRAL<br>HONG KONG, K3 00000                           |               | X         |         |       |
| Ally Bridge Group Innovation Capital Partners III, L.P.<br>UNIT 3002-3004, 30TH FLOOR,<br>GLOUCESTER TOWER, THE LANDMARK, CENTRAL<br>HONG KONG, K3 00000 |               | X         |         |       |
| Li Bin<br>UNIT 3002-3004, 30TH FLOOR,<br>GLOUCESTER TOWER, THE LANDMARK, CENTRAL<br>HONG KONG, K3 00000  |               | X         |         |       |
| Yu Fan<br>UNIT 3002-3004, 30TH FLOOR,<br>GLOUCESTER TOWER, THE LANDMARK, CENTRAL<br>HONG KONG, K3 00000  |               | X         |         |       |

## Signatures

/s/ Yu Fan on behalf of himself and each other reporting person

04/17/2017

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Persons are making this joint, single filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act 1934 as amended (the "Act").
- The Form 4 is filed by and on behalf of each of the following persons (each a "Reporting Person"): (i) ABG II-SO Limited ("ABG II-SO"), a British Virgin Islands limited company, (ii) Ally Bridge Group Capital Partners II, L.P., a Cayman Islands limited partnership, (iii) Ally Bridge LB Healthcare Master Fund Limited ("ABG LB"), a Cayman Islands limited company, (iv) Ally Bridge LB Management Limited, a Cayman Islands limited company, (v) ABG SRNE Limited ("ABG SRNE"), a British Virgin Islands limited company, (vi) Ally Bridge Group Innovation Capital Partners III, L.P., a Cayman Islands limited company, (vii) ABG Management Ltd., a Cayman Islands limited partnership, (viii) ABG Innovation-SO Limited ("ABG Innovation"), a British Virgin Islands limited company,
- (2) (ix) Mr. Fan Yu, a director of ABG LB and a shareholder and director of Ally Bridge LB Management Limited, and the sole shareholder and director of ABG Management Ltd., and (x) Mr. Bin Li, a director and executive officer of ABG LB and a shareholder and director of Ally Bridge LB Management Limited.
- (3) Each Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for the purpose of Section 16 of the Act or otherwise, the beneficial owner of any securities covered by this statement. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
- (4) ABG II-SO directly owns 1,397,853 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Capital Partners II, L.P., as parent of ABG II-SO, (ii) ABG Management Ltd., as manager of Ally Bridge Group Capital Partners II, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
- (5) ABG LB directly owns (i) 1,441,441 shares of common stock of the Issuer and (ii) warrants to purchase 432,432 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge LB Management Limited, as manager of ABG LB, (ii) Mr. Fan Yu, as a shareholder and director of Ally Bridge LB Management Limited, and (iii) Mr. Bin Li, as a shareholder and director of Ally Bridge LB Management Limited.
- (6) ABG SRNE directly owns (i) 3,243,242 shares of common stock of the Issuer and (ii) warrants to purchase 972,972 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Innovation Capital Partners III, L.P., as owner of the sole voting share of ABG SRNE, (ii) ABG Management Ltd., as manager of Ally Bridge Group Innovation Capital Partners III, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
- (7) ABG Innovation directly owns 1,500,000 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Innovation Capital Partners III, L.P., as owner of the sole voting share of ABG Innovation, (ii) ABG Management Ltd., as manager of Ally Bridge Group Innovation Capital Partners III, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
- (8) The warrants are exercisable at any time on or after May 31, 2016.
- (9) The warrants are exercisable at any time on or after June 7, 2016.
- (10)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.